Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content
Fig. 7 | Biological Research

Fig. 7

From: Neuroprotective effects of the PPARβ/δ antagonist GSK0660 in in vitro and in vivo Parkinson’s disease models

Fig. 7

(A-B) WB and relative densitometric analysis for Parkin and DJ-1 in control and treated cells. (C) Proteasome activity assay to evaluate chymotrypsin-like, trypsin-like, and caspase-like activity in control and treated cells. (D) Western blotting representative membrane images of proteasome configuration. Data are mean ± SEM of 3 different experiments run in triplicate (n = 3)

Back to article page